financetom
Business
financetom
/
Business
/
CCI likely to give in-principle nod to Axis Bank-Max Life deal, say sources
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CCI likely to give in-principle nod to Axis Bank-Max Life deal, say sources
Jan 7, 2021 10:53 AM

The Competition Commission of India (CCI) is likely to give an in-principle nod to Axis Bank-Max Life deal, sources told CNBC-TV18 on Thursday. Axis Bank holds about 2 per cent in Max Life Insurance.

Share Market Live

NSE

On completion of the deal, Axis Bank's stake in Max Life will increase to 9.9 percent. In addition to this, Axis Capital and Axis Securities will together acquire 3 percent in Max Life, sources said.

Sources added that Axis has a right to increase its shareholding by 7 percent in Max Life to a maximum of 19.99 per cent.

More details are awaited.

First Published:Jan 7, 2021 7:53 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Stellantis to idle Michigan plant for several weeks due to engine shortage
Stellantis to idle Michigan plant for several weeks due to engine shortage
Apr 3, 2025
April 3 (Reuters) - Chrysler-parent Stellantis ( STLA ) said on Thursday it is idling a plant in Warren, Michigan, for several weeks due to a shortage of engines. It said the issue is unrelated to new U.S. auto tariffs. The automaker said it is allocating all available engines to support production of the Ram 1500 at the Sterling Heights...
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
Apr 3, 2025
(Reuters) -The U.S. Food and Drug Administration has approved expanded use of Amgen's ( AMGN ) drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday. The drug, also known as inebilizumab, has now become the first FDA-approved treatment for Immunoglobulin G4-related disease (IgG4-RD), a rare condition in...
Sector Update: Consumer
Sector Update: Consumer
Apr 3, 2025
03:35 PM EDT, 04/03/2025 (MT Newswires) -- Consumer stocks were mixed late Thursday afternoon, with the Consumer Staples Select Sector SPDR Fund (XLP) rising 0.6% and the Consumer Discretionary Select Sector SPDR Fund (XLY) dropping 6.1%. In sector news, President Donald Trump's auto tariffs will likely cost US car buyers about $30 billion in the first year, assuming carmakers will...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved